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204Objective: This trial was undertaken to determine the safety and efficacy of preoperative aspirin administration
in a contemporary cardiac surgical practice setting.
Methods: This randomized, double-blind, parallel-group, single-center trial involved patients with stable cor-
onary artery disease who were assigned to receive either 300 mg of aspirin or placebo the night before coronary
bypass surgery. Using a random digit table, patients were allocated to receive the tablet from 1 of the 40 coded
bottles containing either aspirin or placebo. Patients, surgeons, anesthetists, and investigators were all masked to
treatment allocation. The primary safety end points were as follows: more than 750 mL of bleeding during the
first postoperative 12 hours and more than 1000 mL of total discharge from the chest drains. The secondary ef-
ficacy end point was a composite of cardiovascular death, myocardial infarction, or repeat revascularization.
Results:A total of 390 patients were allocated to aspirin (387 analyzed) and 399 to placebo (396 analyzed). The
follow-up median was 53 months. Fifty-four placebo recipients and 86 aspirin recipients bled more than 750 mL
in the first 12 hours (odds ratio [OR], 1.81; 95% confidence interval [CI], 1.25-2.63), while total chest drain
discharge was above 1000 mL in 96 placebo and 131 aspirin recipients (OR, 1.60; 95% CI, 1.17-2.18). Preop-
erative aspirin decreased the long-term hazard of nonfatal coronary event (infarction or repeat revasculariza-
tion)—hazard ratio (HR), 0.58 (95% CI, 0.33-0.99)—and tended to decrease the hazard of a major cardiac
event (cardiovascular death, infarction, or repeat revascularization—HR, 0.65 [95% CI, 0.41-1.03]).
Conclusions: Performing coronary grafts on aspirin is associated with increased postoperative bleeding but may
decrease the long-term hazard of coronary events. (J Thorac Cardiovasc Surg 2012;144:204-9)Supplemental material is available online.The administration of aspirin shortly after coronary artery
bypass grafting (CABG) has been shown to improve graft
patency, reduce the number of ischemic events (myocardial
infarction [MI] and stroke), and improve survival.1 To be ef-
fective in preventing graft occlusion, treatment must be
started within 12 hours2 or ideally even 6 hours3 of
CABG. Currently, many surgeons continue aspirin adminis-
tration until surgery,4 despite current guidelines from The
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The Journal of Thoracic and Cardiovascular Surgguidelines suggest that aspirin be discontinued in patients
without acute coronary syndrome 3 and 7 days before sur-
gery, respectively, and restarted within 6 hours and 48 hours
after CABG, respectively.
The practice of continuing aspirin until surgery is based
on little evidence. The meta-analysis of 8 randomized trials
including 805 patients and 14 observational studies (4485
patients) showed that preoperative aspirin increases postop-
erative bleeding, transfusion requirements, and chest reex-
ploration for bleeding, while having no significant effect
on MI or death.7 These studies were outdated and under-
powered and the authors called for a new randomized trial
of preoperative aspirin in the settings of contemporary car-
diac surgical practice.7
The current trial was constructed to answer these
questions.METHODS
Study Design
We conducted a single-center, 1:1 randomized, double-blind, placebo-
controlled trial to assess whether a single preoperative 300-mg dose of as-
pirin, 1 night before CABG, is safe and effective. Patients subjected to their
first-time elective CABG, for whom aspirin was stopped 7 days before sur-
gery, were eligible for the study. The exclusion criteria were as follows: age
above 75 years, the need for concomitant cardiac procedure other than
CABG, previous cardiac surgery, bleeding disorders, full blood count orery c July 2012
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CABG ¼ coronary artery bypass grafting
CI ¼ confidence interval
CPB ¼ cardiopulmonary bypass
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Minternational normalized ratio or activated partial thromboplastin time out-
side normal range, blood product transfusion within the past 30 days, and
allergy to aspirin.
The patients were randomized to receive a single 300-mg tablet of aspi-
rin (or matching placebo) the night before surgery. The use of cardiopulmo-
nary bypass (CPB), myocardial protection method, and antifibrinolytic
therapy were left to the surgeon’s discretion. We prespecified to look for
the interaction of these factors with study group assignment. During the
procedure, after heparin reversal, hemostasis was achieved and all open
cavities were thoroughly suctioned before sternal closure. The drains’ dis-
charge was monitored and the drains were removed the next evening. The
decision to reexplore the chest and to administer blood products was left to
the operating surgeon and the team on call, who were all blinded to the pa-
tient allocation. No formal protocol was enforced, but we generally reex-
plore the chest if the bleeding exceeds 200 mL/h in the first 4 hours
postoperatively or 100mL/h thereafter and transfuse packed red blood cells
if the hematocrit level drops below 25%. No autologous blood transfusions
or chest aspirate reinfusions were used. Daily, 300mg of aspirin was started
6 hours postoperatively in all patients.
The primary end points with respect to safety were the drainage of more
than 750mL over the first postoperative 12 hours andmore than 1000mL in
total. We also report both 12-hour and total chest tube drainage. Secondary
prespecified safety outcomes included the need for chest reexploration, the
need for blood product transfusion, and the postoperative hematocrit drop
below 25%.
The safety end points of postoperative cardiac biomarker levels, crude
mortality, and major adverse cardiovascular event (eg, 30-day death,
stroke, MI) were considered secondary.
We have calculated that we would need to enroll 800 patients for the
power above 90% to detect a 50% increase of relative risk of discharging
more than 1000mL from the chest drains, assuming an event rate of 20% in
patients operated on without aspirin pretreatment.
Although the study was first designed to look for the effect of aspirin
administration on postoperative bleeding, transfusions, and chest reexplo-
ration, it was later decided to continuewith a long-term efficacy analysis. In
this situation, all long-term efficacy end points should be considered sec-
ondary. We looked specifically for death, cardiovascular death, stroke,
MI, and repeat revascularization. We also decided to look for aggregate
of cardiovascular death, MI or repeat revascularization (major adverse car-
diovascular event), as well as MI or repeat revascularization (major nonfa-
tal coronary event), hoping that these coronary artery–related composite
end points would be influenced most by preoperative aspirin use. Inasmuch
as the patients’ recruitment lasted 38 months, we needed to follow them up
for another 36 months to detect a 30% decrease in the relative hazard of
combined death, MI, or repeat revascularization with the power above
80%, assuming an event rate of 10% per 3 years and the 10% loss to
follow-up.
Randomization and Masking
The 800 tablets containing either placebo or 300 mg of aspirin were in-
discernible and dispensed in 40 coded bottles, each containing 20 tablets.
The patients were randomized by a random digit table to receive a tabletThe Journal of Thoracic and Cafrom 1 of the bottles the night before surgery. The tablets were prepared
and the bottles were coded by an independent pharmacist who was not in-
volved in the patients’ recruitment, sequence generation, or implementa-
tion. Patients, surgeons, anesthetists, nurses, and researchers were all
blinded as to the content of the bottles.
The study was approved by the local bioethics committee and informed
consent was obtained from all patients.
We used the Shapiro-Wilk test to confirm normal distribution of para-
metric data. Accordingly, the data were presented as means and standard
deviations and were compared using the t test, or as median with interquar-
tile range and compared with the Mann-Whitney test. Patients’ character-
istics and outcomes were presented as percentages and compared using the
c2 test. To estimate the relative risk of the outcome in the aspirin group, we
calculated the odds ratio (OR) with 95% confidence interval (CI). The
parametric outcomes were presented either as a median with interquartile
range or as a mean with 95% CI.
Cumulative event rates from the time of randomization were estimated
using the Kaplan-Meier method and compared using the log–rank test. The
hazard ratio (HR) with 95%CI was derived from the Cox proportional haz-
ards model. We used SPSS 14.0 for Windows (SPSS, Inc, Chicago, Ill) for
statistical analysis.
RESULTS
Study Population
Between June 9, 2003, and July 1, 2006, we randomized
789 patients: 390 received aspirin and 399 placebo. Six pa-
tients were excluded from the analysis. The CONSORT
flow diagram is presented in the online supplement
(Figure E1). Five (1%) patients were lost-to-follow-up after
discharge. They were censored in all analyses on their
discharge date. Another 74 (10%) patients (34 [9%] in
the aspirin and 40 [10%] in the placebo group [P ¼ .6])
were lost-to-follow-up at some later stage and censored in
analyses on the day of last contact; however, their mortality
data (with the cause of death) were brought up to date at da-
tabase closure by checking with the national death register.
The median duration of follow-up was 53.3 months
(42.1-63.3 months).
Baseline demographic and clinical characteristics of pa-
tients are summarized in Table E1.
Operative Procedure
A median of 3 grafts per patient were constructed in both
groups (P¼ .8). There were no significant differences in the
operative conduct between the groups. The details of the op-
eration are summarized in Table 1.
Safety Outcomes
The chest drains were removed 30.8 hours (27.7-32.2)
and 31.2 hours (27.8-32.2) (P ¼ .4) after the operation in
the placebo and aspirin groups, respectively. Fifty-four
(14%) patients receiving placebo and 86 (22%) patients re-
ceiving aspirin bled more than 750 mL in the first 12 hours
(OR, 1.81; 95% CI, 1.25-2.63; P ¼ .002). Total chest drain
discharge was more than 1000 mL in 96 (24%) placebo and
131 (34%) aspirin patients (OR, 1.60; 95% CI, 1.17-2.18;
P ¼ .003). The patients who received a single preoperativerdiovascular Surgery c Volume 144, Number 1 205
TABLE 1. Operative conduct
Aspirin
(n ¼ 387)
Placebo
(n ¼ 396) P
No. of distal anastomoses, median
(Q1-Q3)
3 (2-3) 3 (2-3) .8
LITA use, n (%) 382 (99) 392 (99) .8
RITA use, n (%) 14 (4) 9 (2) .3
RA use, n (%) 26 (7) 30 (8) .6
Total arterial revascularization,
n (%)
51 (13) 58 (15) .6
Sequential grafts, n (%) 21 (5) 24 (6) .7
Endarterectomy, n (%) 1 (0) 1 (0) .99
OPCAB, n (%) 74 (19) 72 (18) .7
On-pump: n (%) 313 (81) 324 (82)
CPB time (min), median
(Q1-Q3)
62 (50-76) 64 (50-76) .8
AXC time (min), median
(Q1-Q3)
35 (28-44) 36 (29-44) .4
Normothermia, n (%) 298 (95) 311 (96) .8
Miniplegia, n (%) 77 (25) 65 (20) .2
Prophylactic tranexamic acid,
n (%)
110 (35) 130 (40) .2
Prophylactic aprotinin, n (%) 72 (23) 57 (18) .1
Procedure time (min), median
(Q1-Q3)
160 (140-180) 160 (135-180) .7
Q1-Q3, Interquartile range; LITA, left internal thoracic artery; RITA, right internal
thoracic artery; RA, radial artery; OPCAB, off-pump coronary artery bypass; CPB,
cardiopulmonary bypass; AXC, aortic crossclamp.
TABLE 2. Blood product transfusions in postoperative period
Aspirin
(n ¼ 387)
Placebo
(n ¼ 396) P
Transfusion of PRBCs (units)
Mean (95% CI) 0.98 (0.81-1.16) 0.77 (0.62-0.93)
Median 0 0 .06
Quartile 1–quartile 3 0-2 0-1
Range 0-14 0-13
Transfusion of PRBCs, no.
of patients (%)
144 (37) 126 (32) .1
FFP transfusion (units)
Mean (95% CI) 0.76 (0.60-0.92) 0.46 (0.34-0.58)
Median 0 0 .001
Quartile 1–quartile 3 0-1 0-0
Range 0-15 0-11
FFP transfusion, no. of
patients (%)
107 (28) 69 (17) .001
Platelet transfusion (units)
Mean (95% CI) 0.06 (0.03-0.10) 0.02 (0.01-0.04)
Median 0 0 .045
Quartile 1–quartile 3 0-0 0-0
Range 0-3 0-1
Platelet transfusion, no.
of patients (%)
18 (5) 9 (2) .07
PRBCs, Packed red blood cells; CI, confidence interval; FFP, fresh frozen plasma.
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M300-mg dose of aspirin discharged 820 mL (630-1107) in
total, and those who received the placebo discharged 750
mL (575-1000) (P ¼ .006). The mean difference was esti-
mated at 68 mL (95% CI, 15-124 mL) (Figure 1).
No difference in the need for chest reexploration was
observed: 19 (5%) versus 15 (4%) (P ¼ .4) in the aspirin
and placebo groups, respectively (OR, 1.31; 95% CI,
0.66-2.62). Sixty patients in the placebo group (15%) andFIGURE 1. Chest drain discharge. Data are presented as median with in-
terquartile range. Whiskers present 10th and 90th percentiles, and points
present fifth and 95th percentiles.
206 The Journal of Thoracic and Cardiovascular Surg86 (22%) in the aspirin group experienced a hematocrit
level below 25% (OR, 1.60; 95% CI, 1.11-2.30;
P ¼ .01). We also observed some increase in blood product
administration in the aspirin group (Table 2).
Efficacy Outcomes
We observed early major adverse cardiovascular event
(death or MI or stroke within 30 days of surgery) in 12
(3%) patients in the aspirin group and 19 (5%) in the pla-
cebo group (P ¼ .2) (Table 3). No differences in postoper-
ative cardiac marker levels were observed (Figure E2).
Although we had no influence on long-term postopera-
tive therapy, the data gathered on the last follow-up con-
firmed that they conformed to current guidelines and did
not differ between the groups (Table E2).
A major cardiac event (cardiovascular death or MI or re-
peat revascularization, percutaneous in all cases) occurred
in 30 (8%) aspirin and 45 (11%) placebo patients. The
HR for preoperative aspirin was estimated at 0.65 (95%TABLE 3. Early postoperative course
Aspirin (n ¼ 387) Placebo (n ¼ 396) P
MACE (30 d), n (%) 12 (3) 19 (5) .2
Death (30 d), n (%) 5 (1) 5 (1) .97
Perioperative MI, n (%) 8 (2) 14 (4) .2
Perioperative stroke, n (%) 2 (1) 3 (1) .7
IABP, n (%) 13 (3) 23 (6) .1
MACE, Major adverse cardiovascular event (death or stroke or myocardial infarc-
tion); MI, myocardial infarction; IABP, intra-aortic balloon pump.
ery c July 2012
Deja et al Perioperative ManagementCI, 0.41-1.03; P¼ .06) (Figure 2, A). We observed 18 (5%)
deaths in the aspirin group and 22 (6%) in the placebo
group. Of those, 11 died of noncardiac causes: 1 in a car ac-
cident, 1 of pneumoconiosis, and 9 of neoplastic disease.
Overall mortality and cardiovascular mortality did not dif-
fer between the groups, with HR for preoperative aspirin
0.83 (95% CI, 0.45-1.55; P ¼ .5) and 0.62 (95% CI,
0.29-1.31; P ¼ .2), respectively (Figure 2, B, Figure E3).
We found that a nonfatal coronary event, defined as MI or
repeat revascularization, was more likely to occur in the pla-
cebo group: HR for preoperative aspirin was 0.58 (95% CI,
0.33-0.99; P ¼ .046) (Figure 2, C). The HR of MI was 0.59
(95% CI, 0.30-1.18; P¼ .1) and of repeat revascularization
0.66 (95% CI, 0.31-1.43; P ¼ .3).Subgroup Analysis
No significant interaction of prespecified factors with
study group assignment was observed in the cases of early
outcomes (Figure E4).
Preoperative aspirin prevented long-term major cardiac
events (cardiovascular death or MI or repeat revasculariza-
tion) in patients operated on with CPB (HR, 0.54; 95% CI,
0.31-0.93; P¼ .03) and in patients receiving antifibrinolytic
therapy (HR, 0.40; 95% CI, 0.17-0.97; P ¼ .04); however,
in neither case was the interaction with group assignment
significant (P ¼ .2 and P ¼ .3, respectively) (Figure E5).
The only significant interaction was the one between the in-
fluence of preoperative aspirin and the use of CPB in case of
the hazard of long-term coronary event (MI or repeat revas-
cularization) (P ¼ .02). This could suggest that the benefi-
cial effect of aspirin may only be present in patients whose
operation is performed on-pump (HR, 0.37; 95% CI,
0.19-0.75; P ¼ .005) (Figure E5)FIGURE 2. A, Probability of major cardiac event—cardiovascular (CV)
death, myocardial infarction (MI), or repeat revascularization in the postop-
erative period. B, Probability of CV death in the postoperative period. C,
Probability of major nonfatal coronary event—MI or repeat revasculariza-
tion in the postoperative period. Lines are the Kaplan-Meier estimates with
standard error. P is from log–rank comparison.
P
MDISCUSSION
This study is, to our knowledge, the largest randomized
trial of preoperative aspirin administration in cardiac sur-
gery. It definitively shows that, in the settings of a contempo-
rary cardiac surgical practice, preoperative aspirin
administration increases the risk of postoperative bleeding.
The results can be viewed in 2 ways. One may question the
70-mL average difference of total drain discharge as clini-
cally unimportant (although statistically significant) and
not resulting in an increased need for chest reexploration.
On the other hand, the chance of bleeding in excess of 750
mL increased nearly twice, there was a 50% increase in
the risk of the hematocrit value dropping below 25%, and
the risk of receiving more than 1 unit of packed red blood
cells (not a prespecified end point) was significantly in-
creased (OR, 1.45; 95%CI, 1.04-2.02; P¼ .03).We believe
the fact that some patients may have considerably increased
postoperative bleeding owing to preoperative aspirin to be
clinically more meaningful than the comfortingly smallThe Journal of Thoracic and Cadifference in median drainage. However, we acknowledge
that some clinicians may argue the opposite.
Increased postoperative bleeding is not associated with
any obvious decrease in early ischemic end points. Even
the biomarker levels remained virtually the same in both
groups. In view of the rather low incidence of early major
adverse cardiovascular events, our study was underpowered
for the detection of difference. Also, the fact that all patients
received early postoperative aspirin might have mitigated
the possible difference.1,2 Still, our results are inrdiovascular Surgery c Volume 144, Number 1 207
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Magreement with most other studies,7-13 including a recent
retrospective report by Jacob and associates14 based on
more than 4000 patients operated on at the ClevelandClinic.
Two large retrospective studies15,16 showed no aspirin
influence on postoperative chest drain discharge. The
group assignment in both studies was based on whether
or not patients received aspirin within the past 5 or 7
preoperative days, and true data on the proximity of
aspirin therapy to CABG, as well as aspirin dosage, are
lacking in both articles. Meanwhile, aspirin therapy within
48 hours preoperatively may be crucial for the outcome.7,11
We decided to follow the patients up to detect end points
that could be related to coronary events. Our study is the
first, to our knowledge, to show some long-term benefit of
preoperative aspirin administration. Preoperative aspirin
tended to decrease the chance of a major cardiac event
and decreased by 40% the long-term hazard of a coronary
event developing (MI or repeated revascularization). How-
ever, these findings need to be treated with caution inas-
much as they are all secondary findings and result from
analyses that were not initially planned.
It may appear strange that preoperative aspirin affects the
long-term outcome without much effect on the early results
of surgery, especially because it has primarily been shown
to prevent mainly the early thrombotic occlusion and not
the other types of graft disease.17 It may well be that sub-
clinical, early closure of venous grafts could explain the
need for revascularization and later MI coming to clinical
attention.2,18 Obviously, this is just a speculation and
would require angiographic data to be confirmed.
Platelet activation soon after surgery is much less pro-
nounced in off-pump compared with on-pump CABG.19
This makes preoperative aspirin redundant for off-pump
CABG, provided it is administered almost immediately
postoperatively, and may explain why a statistically signif-
icant decrease in the incidence of major cardiac events is
visible only in patients operated on with CPB.
Limitations of the Study
The obvious limitation of our study is that patients were
receiving a single 300-mg dose of aspirin before surgery,
having stopped its use a week earlier. This is distinct from
regularly administered aspirin right up until the operation,
which would more accurately mimic the usual real-life
course of events. We are aware of the viewpoint that con-
tinuing aspirin therapy until surgery may decrease the
chance of acute coronary syndrome developing preopera-
tively.20 The design of our study does not allow for disprov-
ing such a possibility. This design was chosen, as it was the
practice in our department to stop the aspirin a week before
surgery in all patients, and patients were recruited into the
study after being admitted for surgery. It made blinding eas-
ier and the groups pure from the methodologic point of
view. Because nearly 90% of the antiplatelet effect of208 The Journal of Thoracic and Cardiovascular Surgaspirin is obtained as early as 6 hours after administration
of a single dose21 and is irreversible for the platelet lifetime,
the result of our study can be easily extrapolated for contin-
uous preoperative aspirin use.
We did not use a formal protocol regarding the chest re-
exploration and blood product transfusion, other than the
criteria stated in the ‘‘Methods’’ section. In particular, we
had no strict criteria regarding administration of the fresh
frozen plasma and platelets. The decision was always
made by the team on call, based on their clinical judgment
including chest drainage, hematocrit level, international
normalized ratio, and platelet level. We decided it was sci-
entifically more appropriate to rely on the blinding and ran-
domization, rather than create an artificial protocol not
reflecting our everyday practice.
Another major limitation of the study is the inclusion of
heterogeneous groups of patients, operated on with or with-
out CPB, as well as those receiving antifibrinolytic therapy.
However, such a design of the study reflects the real life
clinical practice in our setting. We tried to deal with these
confounders by planning separate analyses of these prespe-
cified subgroups. No significant interaction between the use
of antifibrinolytics and treatment assignment was found.
The result, suggesting that the benefit of preoperative aspi-
rin administration might be limited to patients operated on
on-pump, should be treated with extreme caution, coming
from a subgroup analysis of a secondary outcome.
We excluded patients older than 75 years, who constitute
a big part of contemporary practice. Similarly, we recruited
only the patients with stable coronary artery disease, mak-
ing the study less generalizable. It seems that the early effi-
cacy outcomes might have differed more if the patients with
acute coronary syndrome were included.
Furthermore, as stated earlier, the study was not primarily
designed to examine the efficacy outcomes and therefore
cannot give definite answers regarding the benefit of preop-
erative aspirin use. This would require a larger, multicenter
randomized trial. Our study may help in designing such
a trial and calculating the numbers needed to recruit. With
a small number of end points, a trial aimed at definitively
proving or disproving an early benefit of preoperative aspi-
rin administration may require in excess of 4000 patients to
achieve 80% power.
Finally, our study is somewhat dated. However, with the
current practice of continuing aspirin right up to the opera-
tion,4 it may be even more difficult to organize such a trial
nowadays.
CONCLUSIONS
Our data add to current knowledge regarding the risks
and benefits of preoperative aspirin therapy. In the era
when continuing aspirin up until the operation has become
routine despite the lack of evidence to support this practice,
our data suggest that some increase in postoperativeery c July 2012
Deja et al Perioperative Managementbleeding, with an accompanying moderate rise in the trans-
fusion rate, might be the price to pay for expected decrease
of the hazard of nonfatal MI or repeat revascularization af-
ter CABG.
We thank all the surgeons of the Second Department of Cardiac
Surgery for agreeing to include their patients in the trial. We thank
Professor Tadeusz Wilczok DSc PhD for his assistance with prep-
aration of aspirin/placebo tablets. We appreciate the editorial help
of Piers Murphy (Emmanuel College, University of Cambridge).
References
1. Mangano DT. Aspirin and mortality from coronary bypass surgery. N Engl
J Med. 2002;347:1309-17.
2. Goldman S, Copeland J, Moritz T, Henderson W, Zadina K, Ovitt T, et al. Saphe-
nous vein graft patency 1 year after coronary artery bypass surgery and effects of
antiplatelet therapy. Results of a Veterans Administration Cooperative Study.
Circulation. 1989;80:1190-7.
3. Goldman S, Copeland J, Moritz T, Henderson W, Zadina K, Ovitt T, et al. Start-
ing aspirin therapy after operation. Effects on early graft patency. Department of
Veterans Affairs Cooperative Study Group. Circulation. 1991;84:520-6.
4. ElBardissi AW, Aranki SF, Sheng S, O’Brien SM, Greenberg CC, Gammie JS.
Trends in isolated coronary artery bypass grafting: an analysis of the Society
of Thoracic Surgeons adult cardiac surgery database. J Thorac Cardiovasc
Surg. 2012;143:273-81.
5. Ferraris VA, Ferraris SP, Moliterno DJ, Camp P, Walenga JM, Messmore HL,
et al. The Society of Thoracic Surgeons practice guideline series: aspirin and
other antiplatelet agents during operative coronary revascularization (executive
summary). Ann Thorac Surg. 2005;79:1454-61.
6. Eagle KA, Guyton RA, Davidoff R, Edwards FH, Ewy GA, Gardner TJ, et al.
ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: sum-
mary article. A report of the American College of Cardiology/American Heart
Association Task Force on Practice Guidelines (Committee to Update the 1999
Guidelines for Coronary Artery Bypass Graft Surgery). J Am Coll Cardiol.
2004;44:e213-310.
7. Sun JC, Whitlock R, Cheng J, Eikelboom JW, Thabane L, Crowther MA, et al.
The effect of pre-operative aspirin on bleeding, transfusion, myocardial infarc-
tion, and mortality in coronary artery bypass surgery: a systematic review of ran-
domized and observational studies. Eur Heart J. 2008;29:1057-71.
8. Ferraris VA, Ferraris SP, Lough FC, BerryWR. Preoperative aspirin ingestion in-
creases operative blood loss after coronary artery bypass grafting. Ann Thorac
Surg. 1988;45:71-4.The Journal of Thoracic and Ca9. Morawski W, Sanak M, Cisowski M, Szczeklik M, Szczeklik W, Dropinski J,
et al. Prediction of the excessive perioperative bleeding in patients undergoing
coronary artery bypass grafting: role of aspirin and platelet glycoprotein IIIa
polymorphism. J Thorac Cardiovasc Surg. 2005;130:791-6.
10. Rawitscher RE, Jones JW, McCoy TA, Lindsley DA. A prospective study of as-
pirin’s effect on red blood cell loss in cardiac surgery. J Cardiovasc Surg (Torino).
1991;32:1-7.
11. Weightman WM, Gibbs NM, Weidmann CR, Newman MA, Grey DE,
Sheminant MR, et al. The effect of preoperative aspirin-free interval on red blood
cell transfusion requirements in cardiac surgical patients. J Cardiothorac Vasc
Anesth. 2002;16:54-8.
12. Kallis P, Tooze JA, Talbot S, Cowans D, Bevan DH, Treasure T. Pre-operative
aspirin decreases platelet aggregation and increases post-operative blood
loss—a prospective, randomised, placebo controlled, double-blind clinical trial
in 100 patients with chronic stable angina. Eur J Cardiothorac Surg. 1994;8:
404-9.
13. Michelson EL, Morganroth J, Torosian M, Mac VH III. Relation of preoperative
use of aspirin to increased mediastinal blood loss after coronary artery bypass
graft surgery. J Thorac Cardiovasc Surg. 1978;76:694-7.
14. Jacob M, Smedira N, Blackstone E, Williams S, Cho L. Effect of timing of
chronic preoperative aspirin discontinuation on morbidity and mortality in coro-
nary artery bypass surgery. Circulation. 2011;123:577-83.
15. Dacey LJ, Munoz JJ, Johnson ER, Leavitt BJ, Maloney CT, Morton JR, et al. Ef-
fect of preoperative aspirin use on mortality in coronary artery bypass grafting
patients. Ann Thorac Surg. 2000;70:1986-90.
16. Bybee KA, Powell BD, Valeti U, Rosales AG, Kopecky SL,Mullany C, et al. Pre-
operative aspirin therapy is associated with improved postoperative outcomes in
patients undergoing coronary artery bypass grafting. Circulation. 2005;112(9
Suppl):I286-92.
17. Fuster V, Chesebro JH. Role of platelets and platelet inhibitors in aortocoronary
artery vein-graft disease. Circulation. 1986;73:227-32.
18. FitzGibbon GM, Kafka HP, Leach AJ, Keon WJ, Hooper GD, Burton JR. Coro-
nary bypass graft fate and patient outcome: angiographic follow-up of 5,065
grafts related to survival and reoperation in 1,388 patients during 25 years.
J Am Coll Cardiol. 1996;28:616-26.
19. Ballotta A, Saleh HZ, El Baghdady HW, Gomaa M, Belloli F, Kandil H, et al.
Comparison of early platelet activation in patients undergoing on-pump versus
off-pump coronary artery bypass surgery. J Thorac Cardiovasc Surg. 2007;
134:132-8.
20. Burger W, Chemnitius JM, Kneissl GD, Rucker G. Low-dose aspirin for second-
ary cardiovascular prevention—cardiovascular risks after its perioperative with-
drawal versus bleeding risks with its continuation—review and meta-analysis.
J Intern Med. 2005;257:399-414.
21. Burch JW, Stanford N, Majerus PW. Inhibition of platelet prostaglandin synthe-
tase by oral aspirin. J Clin Invest. 1978;61:314-9.rdiovascular Surgery c Volume 144, Number 1 209
P
M
Assessed for eligibility (n = 970) 
Excluded  (n = 170) 
Not meeting inclusion criteria (n = 123) 
Declined to participate (n = 47)  
Analyzed  (n = 387) 
Excluded from analysis (n = 3) 
Operation postponed (n = 2),  
Surgical ventricular reconstruction added 
to CABG (n = 1) 
No patients lost for early results analysis  
Lost to follow-up (n = 37)   
Long term mortality checked with death 
registry for all patients 
Allocated to aspirin (n = 400) 
Received allocated intervention (n = 390)
Did not receive allocated intervention (tablets 
crushed) (n = 10)
No patients lost for early results analysis 
Lost to follow-up (n = 42 ) 
Long term mortality checked with death 
registry for all patients 
Allocated to placebo (n = 400) 
Received allocated intervention (n = 399)
Did not receive allocated intervention (tablets 
crushed) (n = 1)
Analyzed  (n = 396) 
Excluded from analysis (n = 3) 
Operation postponed (n = 1),  
Mitral valve repair added to CABG (n = 2) 
Randomized (n = 800) 
♦
♦
♦
♦
♦
♦
♦♦
♦
♦
♦
♦
♦
♦
FIGURE E1. CONSORT flow diagram. CABG, Coronary artery bypass grafting.
FIGURE E2. Cardiac markers levels in postoperative period. Data are
presented as median with interquartile range. Whiskers present 10th and
90th percentile; points present fifth and 95th percentiles. CK-MB, Creatine
kinase-myocardial band; POP day, day after surgery.
FIGURE E3. Probability of death in postoperative period. Lines are the
Kaplan-Meier estimates with standard error. P is from the log–rank
comparison.
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FIGURE E4. The influence of preoperative aspirin administration on
early end points in prespecified subgroups. Data are presented as odds ratio
(OR) with 95% confidence interval. P value for interaction between the
factor and the treatment assignment is given. MI, Myocardial infarction.
FIGURE E5. The influence of preoperative aspirin administration on
long-term end points in prespecified subgroups. Data are presented as haz-
ard ratio (HR) with 95% confidence interval. P value for interaction
between the factor and the treatment assignment is given.CV,Cardiovascu-
lar; MI, myocardial infarction.
TABLE E1. Patient characteristics
Aspirin
(n ¼ 387)
Placebo
(n ¼ 396)
Age (y), median (Q1-Q3) 59 (53-66) 59 (54-66)
BMI, median (Q1-Q3) 28 (26-30) 28 (25-30)
Sex (male), n (%) 315 (81) 297 (75)
CCS class
I, n (%) 43 (11) 48 (12)
II, n (%) 177 (46) 162 (41)
III, n (%) 162 (42) 169 (43)
IV, n (%) 5 (1) 17 (4)
NYHA class
I, n (%) 182 (47) 189 (48)
II, n (%) 190 (49) 193 (49)
III, n (%) 15 (4) 14 (4)
Previous MI
0, n (%) 118 (30) 119 (30)
1, n (%) 230 (59) 245 (62)
>1, n (%) 39 (10) 32 (8)
Previous PCI, n (%) 93 (24) 98 (25)
Time from PCI (m), median
(Q1-Q3)
4 (2-7) 4 (2-10)
Coronary vessels affected
One-vessel disease, n (%) 12 (3) 20 (5)
Two-vessel disease, n (%) 68 (18) 65 (16)
Three-vessel disease, n (%) 274 (71) 272 (69)
LM disease, n (%) 33 (9) 39 (10)
LV function
Poor (EF<30%), n (%) 10 (3) 4 (1)
Moderate (EF 30%-50%), n (%) 140 (36) 150 (38)
Good (EF>50%), n (%) 237 (61) 242 (61)
Mild MR, n (%) 99 (26) 96 (24)
History of AF, n (%) 17 (4) 23 (6)
COPD, n (%) 15 (4) 26 (7)
Diabetes mellitus, n (%) 105 (27) 94 (25)
Hypertension, n (%) 331 (86) 320 (81)
Hyperlipidemia, n (%) 343 (89) 340 (86)
History of CVA, n (%) 31 (8) 23 (6)
PVD, n (%) 44 (11) 36 (9)
History of smoking
Past smoker, n (%) 256 (66) 251 (63)
Active smoker, n (%) 36 (9) 45 (11)
Nonsmoker, n (%) 95 (25) 100 (25)
Full blood count
WBC (109/L), median (Q1-Q3) 7.0 (6.0-8.4) 7.0 (6.0-8.2)
RBC (1012/L), median (Q1-Q3) 4.6 (4.4-4.9) 4.6 (4.3-4.8)
Hb (g/dL), median (Q1-Q3) 14.5 (13.9-15.2) 14.3 (13.6-15.0)
Hct (%), median (Q1-Q3) 42 (40-44) 41 (40-43)
Plt (109/L), median (Q1-Q3) 195 (166-226) 195 (168-224)
Creatinine (mmol/L), median (Q1-Q3) 88 (79-106) 88 (79-97)
eGRF (mL/min per 1.73 m2), median
(Q1-Q3)
73.9 (64.4-84.2) 74.8 (64.7-84.3)
Q1-Q3, Interquartile range; BMI, body mass index; CCS, Canadian Cardiovascular
Society; NYHA, New York Heart Association;MI,myocardial infarction; PCI, percu-
taneous coronary intervention; LM, left main coronary artery; LV, left ventricle; EF,
ejection fraction;MR, mitral regurgitation; AF, atrial fibrillation; COPD, chronic ob-
structive pulmonary disease;CVA, cerebral vascular accident; PVD, peripheral vascu-
lar disease; WBC, white blood cells; RBC, red blood cells; Hb, hemoglobin; Hct,
hematocrit; Plt, platelets; eGRF, estimated glomerular filtration rate.
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TABLE E2. Therapy on last contact
Aspirin (n ¼ 330) Placebo (n ¼ 339) P
ACE inhibitors, n (%) 251 (76) 244 (72) .2
Aspirin, n (%) 315 (96) 330 (97) .2
Beta-blockers, n (%) 310 (94) 311 (92) .3
Nitrates, n (%) 39 (12) 39 (12) .9
Insulin, n (%) 8 (2) 10 (3) .7
Statins, n (%) 312 (95) 315 (93) .4
ACE, Angiotensin-converting enzyme.
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